Day 1 at German Biotech Days in Leipzig.

Philip Lössl (SVP) here connecting with researchers and teams across biotech and life sciences.

If you're attending and want to chat, feel free to say hello!

#DBT2026 #Biotech

Attending AACR in San Diego, April 17–22.

Tao Chen, our CEO, will be there meeting researchers and partners to discuss current challenges in cancer research.

If you’re attending, we’d be glad to connect.

#Biotech #AACR26

Heading to German Biotech Days in Leipzig (April 21–22).

Our SVP Philip Lössl will be there connecting with the #proteomics community.

If you’re in the space, happy to chat. 🧬

#biotech #DBT2026

Everyone’s generating more data. Making sense of it is another story.

At analytica (Munich) and NextGen Omics (Boston), we saw the same challenge across spatial and multi-omics.

At Absea, we’re focusing on #spatialbiology and generating clinical #proteomics data.

#biotech

Better raw material quality improves diagnostic clarity. Covering 30+ autoimmune conditions, our portfolio supports assay validation or new panel development in research and clinical labs.

Whether validating existing assays or developing new ones, we can support your work.

We’ve upgraded our autoimmune antigen portfolio with full epitope coverage & native-like folding:

• Jo-1: full-length, N-terminal epitopes
• SNRPB: expanded 80 → 240 aa
• Scl-70: optimized eukaryotic expression
• ANCA antigens: mammalian expression for proper activity

Busy month for the lab:

MS arrived.
New freezer and nitrogen generator.
Back on the conference circuit.
Cubeer round two.

Team dinner last week at a French restaurant, part of our rotating cuisine habit with our multicultural team.

#Biotech #LifeSciences #teammassspec #proteomics

Effects of Calibration Approaches on the Accuracy for LC–MS Targeted Quantification of Therapeutic Protein LC–MS provides a promising alternative to ligand-binding assays for quantification of therapeutic proteins and biomarkers. As LC–MS methodology is based on the analysis of proteolytic peptides, calibration approaches utilizing various calibrators and internal standards (I.S.) have been developed. A comprehensive assessment of the accuracy and reliability of these approaches is essential but has yet been reported. Here we performed a well-controlled and systematic comparative study using quantification of monoclonal-antibody in plasma as the model system. Method development utilized a high-throughput orthogonal-array-optimization, and two sensitive and stable signature-peptides (SP) from different domains were selected based on extensive evaluations in plasma matrix. With the purities of all protein/peptide standards corrected by quantitative amino acid analysis (AAA), five calibration approaches using stable-isotope-labeled (SIL) I.S. were thoroughly compared, including those at peptide, extended-peptide, and protein levels and two “hybrid” approaches (i.e., protein calibrator with SIL-peptide or SIL-extended-peptide I.S.). These approaches were further evaluated in parallel for a 15 time point, preclinical pharmacokinetic study. All methods showed good precision (CV% < 20%). When examined with protein-spiked plasma QC, peptide-level calibration exhibited severe negative biases (−23 to −62%), highly discordant results between the two SP (deviations of 38–56%), and misleading pharmacokinetics assessments. Extended-peptide calibration showed significant improvements but still with unacceptable accuracy. Conversely, protein-level and the two hybrid calibrations achieved good quantitative accuracy (error < 10%), concordant results by two SP (deviations < 15%), and correct pharmacokinetic parameters. Hybrid approaches were found to provide a cost-effective means for accurate quantification without the costly SIL-protein. Other key findings include (i) using two SP provides a versatile gauge for method reliability; (ii) evaluation of peptide stability in the matrix before SP selection is critical; and (iii) using AAA to verify purities of protein/peptide calibrators ensures accurate quantitation. These results address fundamental calibration issues that have not been adequately investigated in published studies and will provide valuable guidelines for the “fit for purpose” development of accurate LC–MS assays for therapeutic proteins and biomarkers in biological matrices.

Protein-level calibration fixes this.

Heavy-labeled proteins added early track workflow losses and remove bias.

Historically, ¹⁵N proteins were expensive → bias accepted.

That’s changing. At Absea, we’re building ¹⁵N protein standards for early workflow calibration.
dx.doi.org/10.1021/ac5001477

Peptide standards are added after digestion.

They never experience:
• sample prep losses
• digestion efficiency
• matrix effects

Nouri-Nigjeh (2014): two peptides disagreed by 40–55%.

Your LC-MS assay validates beautifully. R² > 0.99.

Then you test real plasma QCs with known protein amounts.

Using heavy peptide standards:
→ −23% to −62% systematic bias

So what’s going on?

Final day at #analytica in Munich 👋

It’s been a great few days meeting people across biotech and lab tech.
Our SVP Philip Lössl is there for Absea today.

If you’re around, feel free to say hi or just message us here!

#biotech #labtech #munich

Heading to nextgen omics in boston (march 31 – april 1) to connect with the spatial biology & multi-omics community.

Philip Lossl (SVP) representing Absea.

if you'll be there and want to chat about what we're building, DM us, we have slots for 1:1s 🧬

#NextGenOmics

Tradition in labs: naming the MS. Any suggestions for what we should call it? 🔬

Last week we teased this box. As some of you guessed, it's a Bruker timsUltra AIP.

Enhanced sensitivity and throughput, expanding our analytical capabilities.

Supporting faster progress on our Architectomics pipelines.

Excited to get it running 🔬

#Biotech #teammassspec

heading to analytica in munich (march 24–27) to connect with the lab tech & biotech community!

Philip Lössl (SVP) will be there representing Absea.

if you're attending and want to chat about what we're building, we’ve got a few 1:1 slots 🔬

#analytica

Something big just arrived in the lab again.

Any guesses what’s in this box?

Full reveal next week.

#LabLife #Biotech #TeamScience

Lab upgrade🔬

New freezer.
New nitrogen gas generator.

Heavy lifts, careful moves, and a lot of teamwork to make our lab keep growing.

#LabLife #Biotech #TeamScience

Benchmarking EGF signaling pathway inference using phosphoproteomics and kinase-substrate interactions - Nature Communications To what extent can large-scale approaches accurately reconstruct classic signaling pathways? Here, authors revisit the EGF pathway using phosphoproteomics and kinase-substrate interactions

www.nature.com/articles/s41...

3/3

Up to 90% of data-supported kinase–kinase interactions are absent from ground-truth sets — curated pathways, overexpression screens, correlation data. Not noise — just unexplored.

Prior knowledge > algorithm.

Mikhail Savitski (senior author, Absea SAB) · Clement Potel (co-first author, Absea)

2/3

📢 Publication Spotlight:

We've studied cell signaling like someone searching for lost keys under a streetlight — not because that's where they fell, but because that's where the light is.

New paper in @natcomms.nature.com puts a number on how much we've been missing.

1/3

We organized a casual get-together for the biotech teams in our building — Meet Your New Neighbor.

Simple idea. The kind of thing you assume will happen eventually, until you just start it.

Food, drinks, good conversations.

Thanks to everyone who joined, already planning the next one!

🔗 absea.bio

CDH6, CDH17, CDH3 — from EMT textbooks to clinical-stage ADC programs in just a few years.

Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.

We develop validated antibodies to support that work.👇

References:

1️⃣ www.mcponline.org/article/S153... (MCP) – ¹⁵N standards in proteomics workflows
2️⃣ www.nature.com/articles/s41... (Nature Genetics) – ¹⁵N for genetic/proteomic validation

Multi-site #proteomics studies require cross-lab consistency.

Fold-change comparisons can vary between sites.

¹⁵N-labeled full-length protein standards integrate before extraction and move through digestion and LC-MS, improving cross-site reproducibility and validation robustness.

#Biomarkers

We have a new biosafety cabinet.

Instead of calling movers, we moved it ourselves — across campus to our new lab at Campus Berlin-Buch GmbH.

Five hours.
Careful lifting.
A lot of hands.

And just like that, it’s in the lab.

#Biotech #LabLife

Custom #antibodies often fail in assays where they weren’t tested.

We provide hybridoma supernatants to test in your workflow before clone selection.

Sequenced antibodies remove hybridoma dependence.

4,700+ projects. 18–24 weeks. absea.bio

Paper Highlight: Tumor-reactive T cells aren't only tumor-resident—peripheral blood supplies them during checkpoint therapy.

Li et al. (Cell Stem Cell) GLI model captures this ex vivo. Our anti-LAMP3 KC-1563 identified mature DCs coordinating infiltration.

🔗 www.cell.com/cell-stem-ce...